NA-0111

About NewAmsterdam Pharma Company

NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.

Therapeutic Areas